Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab

[1]  R. Labianca,et al.  Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients , 2011, British Journal of Cancer.

[2]  R. Berardi,et al.  The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. , 2011, The oncologist.

[3]  R. Berardi,et al.  Insulin‐like growth factor 1 expression correlates with clinical outcome in K‐RAS wild type colorectal cancer patients treated with cetuximab and irinotecan , 2010, International journal of cancer.

[4]  I. Soubeyran,et al.  KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications , 2010, Annals of Surgical Oncology.

[5]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[6]  D. Hwang,et al.  Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Funel,et al.  PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Van Cutsem,et al.  Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Andreola,et al.  PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Lenz,et al.  Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab , 2008, Clinical Cancer Research.

[12]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Berardi,et al.  Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options , 2007, British Journal of Cancer.

[14]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[16]  A. Benson,et al.  The continuum of care: a paradigm for the management of metastatic colorectal cancer. , 2007, The oncologist.

[17]  B. LaFleur,et al.  Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[19]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[20]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G Milano,et al.  Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors , 2005, British Journal of Cancer.

[22]  Y. Bang,et al.  Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer , 2005, International journal of cancer.

[23]  R. Berardi,et al.  Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Richard L Schilsky,et al.  Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[25]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[26]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Ellis,et al.  Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Murphy,et al.  Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Hemant K Roy,et al.  AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. , 2002, Carcinogenesis.

[31]  L C Murphy,et al.  Psoriasin (S100A7) expression and invasive breast cancer. , 1999, The American journal of pathology.

[32]  S. Cohen,et al.  Epidermal growth factor , 1972, The Journal of investigative dermatology.